CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-17). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 402 · Search date 2026-07-17 · Methodology v0.6

Tabetri® taheebo extract,
does it really help with Joint and cartilage health and knee discomfort?

30-Second Summary
C
Evidence Grade C · 42 · Safety unknown
A trial exists, but public results and independent replication are insufficient
What the
research shows
A 100-participant, 12-week trial of Tabetri at 600 mg/day was registered, but it was a single Jaseng Medical Foundation-sponsored study centered on subjective joint-pain and function outcomes, and no results were posted. Public efficacy data cannot be independently verified, supporting C with 42 points.
What the
ads claim
Amazonian tradition, cartilage protection, and arthritis improvement are often blended together. No public evidence establishes human cartilage preservation or slowed disease progression.
*

Useful facts when choosing a product

  • It is Korean individually recognized ingredient 2022-2 with a recognized daily intake of 600 mg of Tabetri®.
  • Korean finished products may combine it with vitamins, boswellia, or green-lipped mussel, which must be separated from single-ingredient evidence.
  • The trial product is a standardized ethanolic inner-bark extract, not pau d'arco tea or unstandardized powder.
  • Product labels advise caution in young children, pregnancy or lactation, allergy, and use of anticoagulants or immunosuppressants.
Gap Measurement · Verdict 402 · C 42
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

NCT03757611 tested Tabetri at 600 mg/day for 12 weeks in 100 participants at four Jaseng hospitals. Jaseng Medical Foundation was the sponsor, and the trial assessed subjective pain and function measures, but ClinicalTrials.gov reports no posted results. Park 2017 was an animal and cell study, not human efficacy evidence.

02

Why this is classified as C (42)

A single Jaseng-sponsored 100-participant trial used subjective outcomes, has no posted results, and lacks independent replication, supporting C with 42 points.

Counterpoint. A symptom signal may have been submitted to regulators, but public sources do not permit verification of effect size or primary-endpoint success.

Rejudgment record. Reassessment (cross-check reflected) — A single 100-participant Jaseng-sponsored trial used subjective outcomes, has no posted results, and lacks independent publication or replication

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Knee discomfort and functionCA registered RCT exists, but public results and independent replication are lacking
Structural cartilage health?No human cartilage-preservation evidence was identified

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
NCT0375761112-week multicenter randomized double-blind placebo-controlled trial100Jaseng Medical Foundation; ingredient-related interests not publicly detailedVAS, K-WOMAC, and KSF-36Completed, but no results were posted in the public registry.Key; verification limited
Park et al. 2017MIA rat osteoarthritis and cell study10Unverified; tested Tabetri®Pain behavior, histology, and inflammatory mediatorsPreclinical improvement signals, not human clinical outcomes.Mechanistic support
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-17).

Jaseng Medical Foundation. A 12 Week, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial for the Evaluation of the Efficacy and Safety of Tabetri on Osteoarthritis. ClinicalTrials.gov NCT03757611; study JS-CT-2017-02. Results not posted.
checked
Park JG, Yi YS, Hong YH, et al. Tabetri™ (Tabebuia avellanedae Ethanol Extract) Ameliorates Osteoarthritis Symptoms Induced by Monoiodoacetate through Its Anti-Inflammatory and Chondroprotective Activities. Mediators Inflamm. 2017;2017:3619879. PMID: 29317792. DOI: 10.1155/2017/3619879.
checked
Korea Food Industry Cluster Agency. Individually approved health functional food ingredients: Tabetri® taheebo extract, recognition 2022-2, 600 mg/day. 2024.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-17 · Corrections: none

Cite this verdict

Tabetri® taheebo extract x joint and cartilage health and knee discomfort Evidence Grade C card
[Chamgap] Tabetri® taheebo extract x joint and cartilage health and knee discomfort — Evidence Grade C·42. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/joint-bone/tabetri-taheebo-joint-cartilage-knee/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.